The drugmaker’s revenue rose 5% when adjusted for currency changes, driven by growth in oncology sales.

Breast cancer patients were considering removing their ovaries until the maker of Zoladex 3.6mg said they would give the drug ...

A drug used to treat patients with life-threatening illnesses has received an important update after substantial community ...

July 27 (Reuters) - AstraZeneca has been adjusting its pricing strategy for new drug launches in response to U.S. President ...

AstraZeneca Plc reported higher-than-expected profit, buoyed by blockbuster cancer medicines, as focus turns to the company’s ...

For years, AstraZeneca has commanded one of the richest valuations among large European pharma companies on the assumption that it consistently delivers results.

AstraZeneca delivered solid core EPS growth of 18% YoY, while revenue growth came in line with expectations for the full year ...

AstraZeneca executives told Fierce they are “very confident” in the pharma’s in-house pipeline of antibody-drug conjugates ...

Better-than-expected sales helped Biogen regain the support of investors, while AstraZeneca and GSK worked to convince Wall ...

A late-stage clinical trial failed to miss its primary endpoint, U.K.'s laregst drugmaker said Thursday.

United Kingdom-based biopharmaceutical giant AstraZeneca will add 10 to 15 new projects to the company's research and ...

Daniel covers the intersection of the health industry and the federal government. He reports on corporate influence in government, the health consequences of federal policies, and the politics of ...